| Dimension | Scoring Notes | Score |
|---|---|---|
| Study Design | Human observational studies and some controlled trials in Russia for anxiety, depression, and cognitive function. Russian regulatory approved (similar pathway to Semax). No Western RCT. |
15 / 25 |
| Sample Size | Smaller evidence base than Semax. Studies typically 30-60 patients. Cumulative human exposure limited. |
4 / 20 |
| Replication | Even more concentrated in single Russian research group (Seredenin and colleagues, Zakusov Institute). Minimal independent replication even within Russia. |
5 / 20 |
| Journal Impact Factor | Published in Eksperimental'naya i Klinicheskaya Farmakologiya and similar Russian pharmacology journals. Low Western IF. |
4 / 15 |
| Funding Independence | Russian government/academic funded. Similar to Semax. |
4 / 10 |
| Population Diversity | Russian patient populations only. Narrow. |
1 / 5 |
| Researcher h-Index | Seredenin group (Zakusov Institute of Pharmacology) — credible Russian academic researchers but limited Western database h-Index. |
3 / 5 |